JPS6313968B2 - - Google Patents

Info

Publication number
JPS6313968B2
JPS6313968B2 JP58090856A JP9085683A JPS6313968B2 JP S6313968 B2 JPS6313968 B2 JP S6313968B2 JP 58090856 A JP58090856 A JP 58090856A JP 9085683 A JP9085683 A JP 9085683A JP S6313968 B2 JPS6313968 B2 JP S6313968B2
Authority
JP
Japan
Prior art keywords
endotoxin
acid
methanol
chloroform
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP58090856A
Other languages
English (en)
Japanese (ja)
Other versions
JPS58216121A (ja
Inventor
Erunsuto Ribi Edogaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIBI IMYUNOKEMU RISAACHI Inc
Original Assignee
RIBI IMYUNOKEMU RISAACHI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIBI IMYUNOKEMU RISAACHI Inc filed Critical RIBI IMYUNOKEMU RISAACHI Inc
Publication of JPS58216121A publication Critical patent/JPS58216121A/ja
Publication of JPS6313968B2 publication Critical patent/JPS6313968B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP58090856A 1982-05-26 1983-05-25 精製無毒化エンドトキシン及びその製造方法 Granted JPS58216121A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/382,404 US4436727A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product
US382404 1982-05-26

Publications (2)

Publication Number Publication Date
JPS58216121A JPS58216121A (ja) 1983-12-15
JPS6313968B2 true JPS6313968B2 (en, 2012) 1988-03-29

Family

ID=23508804

Family Applications (2)

Application Number Title Priority Date Filing Date
JP58090856A Granted JPS58216121A (ja) 1982-05-26 1983-05-25 精製無毒化エンドトキシン及びその製造方法
JP62182406A Granted JPS6345225A (ja) 1982-05-26 1987-07-23 精製無毒化エンドトキシンを含有する抗腫瘍性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP62182406A Granted JPS6345225A (ja) 1982-05-26 1987-07-23 精製無毒化エンドトキシンを含有する抗腫瘍性組成物

Country Status (21)

Country Link
US (1) US4436727A (en, 2012)
JP (2) JPS58216121A (en, 2012)
KR (1) KR870000842B1 (en, 2012)
AT (1) AT386337B (en, 2012)
AU (1) AU556532B2 (en, 2012)
BE (1) BE896822A (en, 2012)
CA (1) CA1185899A (en, 2012)
CH (1) CH661526A5 (en, 2012)
DE (1) DE3318569A1 (en, 2012)
DK (1) DK159275C (en, 2012)
FI (1) FI76494C (en, 2012)
FR (1) FR2527613B1 (en, 2012)
GB (1) GB2122204B (en, 2012)
HU (1) HU190491B (en, 2012)
IL (1) IL68713A (en, 2012)
IN (1) IN156144B (en, 2012)
IT (1) IT1164242B (en, 2012)
NL (1) NL194865C (en, 2012)
NO (1) NO154864C (en, 2012)
NZ (1) NZ204298A (en, 2012)
SE (1) SE462017B (en, 2012)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01141942U (en, 2012) * 1988-03-24 1989-09-28
JPH01180041U (en, 2012) * 1988-06-09 1989-12-25
JPH02124341U (en, 2012) * 1989-03-24 1990-10-12

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPS61151157A (ja) * 1984-12-25 1986-07-09 Seiko Instr & Electronics Ltd タンパク質を加水分解する方法
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
WO1990003183A1 (en) * 1988-09-23 1990-04-05 University Of Southern California Immunotherapy vaccine for melanoma tumors
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
TR200100373T2 (tr) 1998-08-07 2001-09-21 University Of Washington İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU4057300A (en) * 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
NZ514818A (en) 1999-04-02 2004-04-30 Corixa Corp Compounds and methods for therapy and diagnosis of lung cancer
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1808180A3 (en) 1999-10-22 2010-12-22 Sanofi Pasteur Limited Modified GP 100 and uses thereof
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
HUP0300054A3 (en) 2000-02-23 2012-09-28 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1741782B1 (en) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
IL152935A0 (en) 2000-05-19 2003-06-24 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and dissaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
AU2002354644C1 (en) 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AU2002362368B2 (en) * 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
DK1581119T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040033213A1 (en) * 2002-02-28 2004-02-19 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
NZ537655A (en) 2002-07-08 2006-12-22 Corixa Corp Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US20040175378A1 (en) 2002-07-15 2004-09-09 Board Of Regents, The University Of Texas System Selected antibody compositions and methods for binding to aminophospholipids
EP2316479B8 (en) 2002-07-18 2015-03-18 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
SI1589934T1 (sl) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
EP1660123B1 (en) 2003-09-02 2013-03-13 GlaxoSmithKline Biologicals s.a. Rotavirus vaccine
US20060147946A1 (en) * 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
ES2422171T3 (es) * 2004-02-11 2013-09-09 Ligocyte Pharmaceuticals Inc Antígenos de carbunco y procedimientos de uso
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
JP2008500984A (ja) 2004-05-28 2008-01-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヴィロソームとサポニンアジュバントを含むワクチン組成物
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
UA97943C2 (ru) 2005-03-31 2012-04-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против инфекции chlamydia
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
EP2136836B8 (en) 2007-04-04 2017-04-12 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
CL2008002361A1 (es) 2007-08-13 2009-08-07 Glaxosmithkline Biologicals Sa Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
CA2704583A1 (en) 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205)
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
EA021393B1 (ru) 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
EP2324062A4 (en) * 2008-07-18 2012-06-06 Id Biomedical Corp Quebec CHIMERIC RSV POLYPEPTIDE ANTIGEN
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
AR075437A1 (es) 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP5830015B2 (ja) 2009-06-05 2015-12-09 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
JP5829210B2 (ja) 2009-07-15 2015-12-09 ノバルティス アーゲー Ｒｓｖｆタンパク質組成物およびそれを作製するための方法
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP2558498B1 (en) 2010-04-13 2016-10-12 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
SG189176A1 (en) 2010-10-15 2013-05-31 Glaxosmithkline Biolog Sa Cytomegalovirus gb antigen
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
HUE048777T2 (hu) 2011-05-13 2020-08-28 Glaxosmithkline Biologicals Sa Pre-fúziós RSV F antigének
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
HRP20190917T1 (hr) 2011-09-16 2019-07-26 Ucb Biopharma Sprl NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
JP2015525784A (ja) 2012-08-03 2015-09-07 インフェクティアス ディジーズ リサーチ インスティチュート 活動性結核菌感染を治療するための組成物及び方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
EP3513806B1 (en) 2012-12-05 2023-01-25 GlaxoSmithKline Biologicals SA Immunogenic composition
US10195259B2 (en) 2013-01-02 2019-02-05 Decoy Biosystems, Inc. Compositions and methods for treatment of cancer using bacteria
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
SMT202400297T1 (it) 2013-03-13 2024-09-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Proteine f del rsv pre-fusione e loro uso
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
BR112016002354A2 (pt) 2013-08-05 2017-09-12 Glaxosmithkline Biologicals Sa composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
US10751410B2 (en) 2013-09-19 2020-08-25 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
US20170224805A1 (en) 2014-02-20 2017-08-10 Vaxart, Inc. Formulations for small intestinal delivery
CA2944768C (en) 2014-04-03 2022-08-30 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
BR112016030096B1 (pt) 2014-06-25 2023-10-03 Glaxosmithkline Biologicals S.A Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
US11352642B2 (en) 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016191553A1 (en) 2015-05-26 2016-12-01 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
CN118045170A (zh) 2015-06-12 2024-05-17 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
EP3423044A4 (en) 2016-03-02 2019-11-20 The Board of Regents of The University of Texas System STING-ACTIVATING NANO VACCINE FOR IMMUNOTHERAPY
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MA43773A (fr) 2016-03-14 2018-11-28 Univ Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
CN116059351A (zh) 2016-04-18 2023-05-05 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
WO2017205225A2 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
IL311086B2 (en) 2016-06-01 2025-03-01 Access To Advanced Health Inst Nanoaluminum particles containing a fixation factor
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
US11850279B2 (en) 2016-07-13 2023-12-26 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
BR112019003462A2 (pt) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
BE1025160B1 (fr) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa Nouveau procédé
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
BR112019021824A2 (pt) 2017-04-19 2020-06-02 Institute For Research In Biomedicine Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
EP3743102A1 (en) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
BR112020027090A2 (pt) 2018-07-31 2021-03-30 Glaxosmithkline Biologicals S.A. Método de purificação de antígenos
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
KR20220035457A (ko) 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4028051A1 (en) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
BR112022005615A2 (pt) 2019-10-02 2022-07-12 Janssen Vaccines & Prevention Bv Peptídeos de staphylococcus e métodos de uso
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
AU2021208493B2 (en) 2020-01-16 2023-03-30 Janssen Pharmaceuticals, Inc. FimH mutant, compositions therewith and use thereof
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
CA3181627A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US20230236205A1 (en) 2020-06-01 2023-07-27 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
MX2023007596A (es) 2020-12-24 2024-02-23 Plant Bioscience Ltd Metodos y enzimas para la producción de derivados del ácido quillaico.
AU2022207740B2 (en) 2021-01-12 2024-06-06 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
EP4291231A1 (en) 2021-02-11 2023-12-20 GlaxoSmithKline Biologicals S.A. Hpv vaccine manufacture
US12290563B2 (en) 2021-04-01 2025-05-06 Janssen Pharmaceuticals, Inc. Production of E. coli 018 bioconjugates
CN117545773A (zh) 2021-04-09 2024-02-09 塞德斯医疗公司 抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP4499817A1 (en) 2022-03-25 2025-02-05 Plant Bioscience Limited Biosynthesis
CN119403935A (zh) 2022-06-15 2025-02-07 葛兰素史克生物有限公司 皂苷的酶促修饰
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
EP4583841A1 (en) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE185031C (en, 2012) *
DE472221C (de) * 1924-04-01 1929-02-25 Kalle & Co Akt Ges Verfahren zur Gewinnung der toxischen Komponenten aus den Aufschluessen von Bakterien
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01141942U (en, 2012) * 1988-03-24 1989-09-28
JPH01180041U (en, 2012) * 1988-06-09 1989-12-25
JPH02124341U (en, 2012) * 1989-03-24 1990-10-12

Also Published As

Publication number Publication date
HU190491B (en) 1986-09-29
AT386337B (de) 1988-08-10
BE896822A (fr) 1983-09-16
DK159275B (da) 1990-09-24
NO154864B (no) 1986-09-29
CH661526A5 (de) 1987-07-31
JPS58216121A (ja) 1983-12-15
DK221883D0 (da) 1983-05-18
FI831749A0 (fi) 1983-05-18
GB8313253D0 (en) 1983-06-22
FR2527613B1 (fr) 1987-02-27
FR2527613A1 (fr) 1983-12-02
IL68713A0 (en) 1983-09-30
FI831749L (fi) 1983-11-27
DE3318569A1 (de) 1984-01-12
IN156144B (en, 2012) 1985-05-25
FI76494B (fi) 1988-07-29
US4436727A (en) 1984-03-13
DE3318569C2 (en, 2012) 1987-10-29
AU556532B2 (en) 1986-11-06
DK159275C (da) 1991-02-18
DK221883A (da) 1983-11-27
AU1461483A (en) 1983-12-01
KR840004510A (ko) 1984-10-22
IT1164242B (it) 1987-04-08
IL68713A (en) 1986-02-28
GB2122204B (en) 1985-12-24
NO831855L (no) 1983-11-28
SE462017B (sv) 1990-04-30
ATA189483A (de) 1988-01-15
SE8302774D0 (sv) 1983-05-18
JPH042573B2 (en, 2012) 1992-01-20
NL194865C (nl) 2003-05-06
NO154864C (no) 1987-01-07
SE8302774L (sv) 1983-11-27
FI76494C (fi) 1988-11-10
IT8321287A0 (it) 1983-05-25
NL8301842A (nl) 1983-12-16
NL194865B (nl) 2003-01-06
NZ204298A (en) 1986-10-08
CA1185899A (en) 1985-04-23
JPS6345225A (ja) 1988-02-26
GB2122204A (en) 1984-01-11
KR870000842B1 (ko) 1987-04-25

Similar Documents

Publication Publication Date Title
JPS6313968B2 (en, 2012)
JPS6256135B2 (en, 2012)
JPS6234730B2 (en, 2012)
US4505900A (en) Refined detoxified endotoxin product
US4877611A (en) Vaccine containing tumor antigens and adjuvants
KR870000843B1 (ko) 피리딘 가용성 추출물의 제조방법
US4505899A (en) Refined detoxified endotoxin product
JPH0556326B2 (en, 2012)
CA1202903A (en) Stable composition and preparation thereof
JPS6254774B2 (en, 2012)
JPS6253485B2 (en, 2012)